CDH1 and gastroesophageal reflux disease: The protection against pepsin-induced cell dissociation, E-cadherin cleavage and MMP induction of amprenavir has suggested a potential therapeutic role for amprenavir in gastroesophageal reflux disease (GERD), recalcitrant to proton pump inhibitor therapy, and for preventing GERD-associated neoplastic changes [157].